PDX Pharmaceuticals, LLC

Lake Oswego, OR 97035

SBIR Award Summary

Total Number of Awards 3
Total Value of Awards $850K
First Award Date 09/20/12
Most Recent Award Date 08/15/17

Key Personnel

Last Name Name Awards Contact
Yantasee Wassana Yantasee 3

3 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-307
Budget: 08/15/17 - 08/14/18

This revised Phase I SBIR proposal aims at developing a topical formulation of siRNA-nanoparticle that delivers siRNA to treat skin fibrosis. Our platform has inherent antioxidant and anti-inflammatory properties, further benefitting the treatment of skin fibrosis for which there is no effective treatment. Upon completion, the platform will have...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 05/16/17 - 05/15/18

This SBIR Fast-Track application focuses on the development of a nanoconstruct for co-delivery of siRNA and chemotherapy drugs to drug-resistant human epidermal growth factor receptor type 2-positive (HER2+) breast cancer. HER2+ breast cancer is a subtype that presents HER2 overexpression and accounts for 15-25% of invasive breast cancers. HER2+...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-11-097
Budget: 09/20/12 - 08/31/13

DESCRIPTION (provided by applicant): Hyperphosphatemia is universal to end stage chronic kidney disease patients and a majority of dialysis patients totaling of 400,000 in the US and 2 million worldwide. Current oral phosphate binders to treat hyperphosphatemia still have many drawbacks, including a high risk of calcification, high costs ($2100-...